Laser-assisted in situ keratomileusis (LASIK) for myopia is the most commonly performed corneal refractive procedure performed in the world today. The use of the excimer laser to reshape the cornea is accomplished utilizing an ultraviolet laser that contains sufficient energy per pulse to disrupt the organic bonds, which reside in the cornea. This allows corneal stromal tissue to be removed in very precise 0.25 micron increments enabling the surgeon to alter the shape of the cornea. Excess energy is dissipated in acoustic and photic forms. There are a number of excimer laser platforms available today for use by surgeons when performing this procedure. Although there have been sporadic articles comparing one or two laser platforms to another, [1] [2] [3] [4] and rarely an article comparing several of the most commonly used excimer lasers, 5 there has not been a recent comprehensive comparison of currently available platforms looking at standard safety and efficacy data. This meta-analysis was undertaken to accomplish that goal.
Cornea
US Ophthalmic Review intended result of "monovision." Finally, the best data, with regards to visual acuity and loss of BCVA, were presented for each platform. At the conclusion of the database search there were 613 articles. One hundred and seventy-four articles were removed due to the fact that they did not examine the parameters in the categories of 1) visual acuity, 2) ± 0.5 D or ± 1 D of refractive accuracy, or 3) loss of >2 lines of BCVA. Seventyfour articles were excluded because they did not concern myopic LASIK for emmetropia. Seventy-one articles were excluded because they were on previously operated eyes. Ten articles were excluded because they were on pathologic eyes (amblyopia for example). Four articles were excluded since they were not in the English language. After application of the inclusion/exclusion criteria, there were 281 usable journal articles with six separate laser platforms with sufficient data for analysis. If data were lacking with regards to these parameters for a particular platform, we reverted to US Food and Drug Administration (FDA) approval studies. [35] [36] [37] [38] [39] This was a common occurrence and even after including FDA-approval data there were still some platforms with no data points in the literature. For example, only two platforms have 20/10 visual acuity data at the 3-month post-op time frame.
The Six Platforms Compared
A comparison analysis of visual outcomes between these six common excimer platforms was performed. These lasers included the following capabilities at the time of use in the journal articles used.
Abbott-Star-S4IR
Capable of performing conventional (phoropter-based) and wavefront- 
Nidek EC5000
This performs conventional and wavefront-guided excimer laser ablations with scanning slit technology. Ablation profiles can be delivered attempting to create a prolate corneal profile over the mesopic pupil while targeting zero or mildly negative spherical aberration. Additionally, a conventional profile can be used with a small optical zone coupled with an aspheric transition zone that is at least 3 mm larger than the optical zone. The aberrometer is a time-based device using dynamic skiascopy.
The speed of the laser is 40 Hz. Pupil tracking and torsion error detection are available.
Schwind Esiris/Amaris
This is the only laser in this analysis that is not FDA approved, but it so commonly used globally and was therefore included. The laser is capable of conventional and wavefront-guided treatments. A Hartmann-Shack aberrometer is utilized. Ablation profiles can take into account keratometry readings and can deliver aspheric profiles.
The speed is 500 Hz and has pupil tracking and dynamic cyclotorsional tracking technology.
Technolas-217Z
This model is capable of performing both conventional and wavefrontguided excimer ablations with a speed of 100 Hz. The platform uses a Hartmann-Shack type of aberrometer. The ablation can be delivered using an aspheric module. Uses flying spot technology to deliver excimer ablation. Pupil tracking and dynamic iris recognition are available.
The final results underwent a statistical analysis in the following manner:
we used a one-tailed two-sample Z-test about proportions. Observed proportions were placed in descending order, then we iteratively tested each against the remaining platforms. If observed proportions were equal: the sample size was the "tie-breaker" as a potential discriminator against lower observed proportions.
Results

Visual Acuity at 1 Month Comparison of Platforms
The following data were recovered from the eligible articles:
Abbott excimer platform-20/10-22 %, 6 20/12.5-81 %, 6 Table 1 ).
Visual Acuity at 3 Months Comparison of Platforms
Abbott excimer platform-20/10-23 %, 6 20/12.5-80 %, 6 The Abbott platform was significantly superior to all the other platforms at acuity levels 20/12.5 and 20/16 (see Table 2 ).
Visual Acuity at 6 Months Comparison of Platforms
The following data were recovered from the eligible articles: The Nidek platform was significantly superior to all the other platforms at acuity level 20/16 (see Table 3 ). No device was superior to all the other devices (see Table 4 ).
Refractive Accuracy at ± 0.5 Diopters Comparison of Platforms
Abbott excimer platform-3 month-87 %, 38 6 month-91 %, Carl Zeiss excimer platform-3 month-94 %, 14 6 month-98 %, 17 12 month-98 % 19 Nidek excimer platform-3 month-91 %, 22 6 month-89 %, 21 12 month-85 % 20 Schwind excimer platform-3 month-96 %, 28 6 month-96 %, 26 12 month-95 % 29 Technolas excimer platform-3 month-98 %, 11 6 month-94 %, 31 12 month-86 % 32 (see Figure 5) The Carl Zeiss platform was superior to all the other platforms at 6 months (see Table 5 )
Refractive Accuracy at ± 1.0 Diopters
Comparison of Platforms
Abbott excimer platform-3 month-95 %, 7 6 month-99 %, 38 12 month-100 % 38 Alcon excimer platform-3 month-98 %, 11 6 month-100 %, 9 12 month-100 % 9
Carl Zeiss excimer platform-3 month-97 %, 14 6 month-no data, 12 month-100 % 19 Nidek excimer platform-3 month-100 %, 22 6 month-100 %, 21 12 month-96 % 20 Schwind excimer platform-3 month-100 %, 28 6 month-90 %, 27 12 month-no data Technolas excimer platform-3 month-100 %, 34 6 month-100 %, 31 12 month-100 % 32 (see Figure 6 ).
No device was superior to all the other devices (see Table 6 ).
Adverse Event-Loss of Best Spectacle-corrected Visual Acuity >2 Lines
Abbott excimer platform-1 month-0 %, 6 3 month-0.4 %, 6 6 month-0 %, 38 12 month-0 %
38
Alcon excimer platform-1 month-0 %, 35 3 month-0 %, 15 6 month-0 %, 9 12 month-0 % 9
Carl Zeiss excimer platform-1 month-0.8 %, 37 3 month-0 %, 14 6 month-0.3 %, 37 12 month-0 %
19
Nidek excimer platform-1 month-1.5 %, 39 3 month-0 %, 23 6 month-0 %, 24 12 month-0.7 %
39
Schwind excimer platform-1 month-no data, 3 month-0.6 %, 26 6 month-0 %, 26 12 month-1.8 %
29
Technolas excimer platform-1 month-1.5 %, 36 3 month-1.2 %, 36 6 month-0.6 %, 36 12 month-3 % 32 (see Figure 7 )
The Abbott and Alcon platforms were superior to all the other devices at the 1 month measurement. At all other time periods, no device was superior to any of the others (see Table 7 ). All devices remained below the 5 % FDA guidance figure.
Discussion
As with any meta-analysis, a legitimate criticism is that the different 
